item management s discussion and analysis of financial condition and results of operations results of operations eleven months ended december  and the years ended january  and during the eleven months ended december   the company reported a net loss of  during this period the company had no contract revenues 
the investment earnings on cash and current investments for the eleven months ended december  was  compared to  for the year ended january  this significant decrease was due to lower average cash balances and interest rates 
total research and development expenditures increased  in the eleven months ended december  over the year ended january  this increase was a result of the increased clinical trial costs associated with the development of the company s products 
these costs included the costs of establishing centers where patients are treated and monitored 
research and development expenses were reduced by approximately  this reduction corresponds with an adjustment of the same amount for unrealized loss on investment securities 
the company allows certain employees to defer a portion of compensation  and the company transfers this amount into an investment account that the employee then directs the investment of the funds 
the related investment securities are held by the company  and are subject to the general creditors of the company 
these employees direct the investment of the funds  and the changes in value in these investments are recognized as unrealized gains and losses in the statement of operations with a corresponding increase or decrease to the carrying value of the investment account 
the same amount is used to adjust research and development expense and the corresponding liability for employees wages and benefits payable 
unrealized holding losses on trading securities and the corresponding decrease in research and development expense totaled approximately  in the eleven month period ending december  and approximately  for the year ended january  unrealized holding gains on trading securities and the corresponding increase in research and development expense totaled approximately  in the year ended january  the company does not accumulate cost information by major development product 
many costs are applicable to more than one product 
we receive reimbursements from our strategic partners for some of our research and development expenses and these expenses are not included in our costs 
we estimate that of our research and development costs are spent on gastrointestinal and reproductive system cancers 
there are no payment or penalty milestones associated with any of the projects  all of which are in phase ii or iii clinical trials 
the company does not speculate on the timing of approvals by regulatory authorities 
during the year ended january   the company reported a net loss of  during this period the company had no contract revenues 
the investment earnings on cash and current investments for the year was  this significant increase was due to higher average cash balances 
total research and development expenditures increased  research and development cash expenditures were approximately  greater in the year ended january  than in the year ended january  this increase was a result of the increased clinical trial costs associated with the development of the company s products 
during the year ended january   the company reported a net loss of  during this period the company had no contract revenues 
investment earnings on cash and current investments for twelve months was less than the  earned in the year ended january  due to lower average cash balances 
although ending cash and investments were approximately  greater than at january   most of the funds were received during the period from october  to january  total research and development expenditures increased approximately  research and development cash expenditures were approximately  greater than in the year ended january  non cash research and development expenses increased approximately  and were related to a company plan whereby individuals may forego immediate receipt of wages  as described above 
in june  the financial accounting standards board fasb issued sfas no 
 accounting for derivative instruments and hedging activities 
sfas no 
establishes accounting and reporting standards for derivative instruments and hedging activities 
sfas no 
requires recognition of all derivative instruments in the statement of financial position as either assets or liabilities and the measurement of derivative instruments at fair value 
in june  the fasb issued sfas no 
 accounting for derivative instruments and hedging activities deferral of the effective date of fasb statement no 
the original effective date for sfas no 
was for all fiscal years beginning after june  as a result of the issuance of sfas no 
 the effective date for sfas no 
is for all fiscal quarters of all fiscal years beginning after june  the adoption of sfas no 
 as amended and interpreted  did not have an impact on the financial statements 
in june  the financial accounting standards board issued statements of financial accounting standards no 
 business combinations  and no 
 goodwill and other intangible assets  effective for fiscal years beginning after december  under the new rules  goodwill and intangible assets deemed to have indefinite lives will no longer be amortized but will be subject to annual impairment tests in accordance with the statements 
other intangible assets will continue to be amortized over their useful lives 
the company believes the adoption of these statements will have no impact on its financial position or results from operations 
in august  the financial accounting standards board issued statement of financial accounting standards no 
 accounting for the impairment or disposal of long lived assets sfas no 

sfas superseded statement of financial accounting standards no 
 accounting for the impairment of long lived assets and for long lived assets to be disposed of  and the accounting and reporting provisions of accounting principles board opinion no 
 reporting the results of operations reporting the effects of disposal of a segment of a business  and extraordinary  unusual and infrequently occurring events and transactions  for the disposal of a segment of a business 
sfas no 
also amended accounting research bulletin no 
 consolidated financial statements  to eliminate the exception to consolidation for a subsidiary for which control is likely to be temporary 
the company believes the adoption of this statement will have no impact on its financial position or results from operations 
inflation and changing prices have not had a significant effect on continuing operations and are not expected to have any material effect in the foreseeable future 
dividend  interest and other income were primarily derived from money market accounts 
liquidity and capital resources the company has financed its operations since inception through the sale of its equity securities and  to a lesser extent  operating revenues from r d limited partnerships to conduct research and development 
these funds provided the company with the resources to acquire staff  construct its research and development facility  acquire capital equipment and to finance technology and product development  manufacturing and clinical trials 
subsequent to year end  on march   the company sold  shares of registered common stock at per share and received net proceeds of million 
subsequent to year end  on february   the company sold  shares of registered common stock at per share and received net proceeds of million 
the selected pro forma financial information summarized below shows the effect of the net proceeds from equity financing transactions received on february  and march  as if the closing of those transactions had occurred  and the net proceeds from those transactions had taken place  on december  balance sheet data pro forma december december  cash and current investments   total assets   total stockholders equity deficit   weighted average shares outstanding   the unaudited pro forma financial information is not necessarily indicative of the company s future results of operations 
the unaudited pro forma financial information should be read in conjunction with this section captioned management s discussion and analysis of financial conditions and results of operations and with our financial statements and related notes included in this report 
during the eleven months ended december   the company received proceeds of approximately million net of approximately million offering costs from the closing of a private financing with several funds 
the company issued  shares of common stock and there were no warrants or options included with this private placement 
approximately  additional shares will be issued subsequent to december  due to an anti dilution provision for the sale of securities less than per share prior to october  during the year ended january   the company received net proceeds of million from the closing of a private financing with several international biotechnology healthcare funds 
the company issued  shares of common stock and there were no warrants or options included with this private placement 
the company has not performed any research for third parties and has no sources of income from operations 
cash flows from investing activities are not anticipated to be significant 
the company has no short or long term debt or lines of credit established 
the company anticipates that the sale of its equity securities will continue to finance operations for the foreseeable future 
during the year ended january   in a private placement the company sold  shares of common stock for  net of expenses 
the company also issued  shares through the exercise of outstanding purchase warrants  resulting in net proceeds of  the company anticipates that its existing capital resources which are composed primarily of cash and short term cash investments  including the proceeds of its private placements and interest thereon  would enable it to maintain its currently planned operations through the year ending december  the company s working capital and capital requirements will depend upon numerous factors  including the following the progress of the company s research and development program  preclinical testing and clinical trials  the timing and cost of obtaining regulatory approvals  the levels of resources that the company devotes to product development  manufacturing and marketing capabilities  technological advances  competition  and collaborative arrangements or strategic alliances with other drug companies  including the further development  manufacturing and marketing of certain of the company s products and the ability of the company to obtain funds from such strategic alliances or from other sources 
critical accounting policies the sec has recently issued financial reporting release no 
 cautionary advice regarding disclosure about critical accounting policies frr  suggesting companies to provide additional disclosure and commentary on those accounting policies considered most critical 
frr considers an accounting policy to be critical if it is important to the company s financial condition and results  and requires significant judgment and estimates on the part of management in its application 
aphton believes the following represent the critical accounting policies of the company as contemplated by frr for a summary of all the company s significant accounting policies  including the critical accounting policies discussed below  see note to the accompanying financial statements 
use of estimates in the preparation of financial statements the preparation of financial statements in conformity with accounting principles generally accepted in the united states requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period 
actual results could differ from those estimates  however management believes such differences are unlikely to be significant 
research and development expenses research and development costs are expensed as incurred 
these costs include internal research and development costs  the salaries of dedicated personnel  the allocated salaries of personnel who also perform general and administrative tasks  the costs of the dedicated research and development facilities and the costs of contracted researchers 
there is no allocation of administrative expense or corporate costs to research and development costs 
income taxes the company accounts for income taxes pursuant to statement of financial accounting standards sfas no 
 accounting for income taxes  which requires an asset and liability approach in accounting for income taxes 
under this method  the amount of deferred tax asset or liability is calculated by applying the provisions of enacted tax laws to the differences in the bases of assets and liabilities for financial and income tax purposes 
income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities 
the company regularly reviews its deferred tax assets for recoverability and establishes a valuation allowance based upon historical losses  projected future taxable income and the expected timing of the reversals of existing temporary differences 
as a result of this review  the company has established a full valuation allowance against its deferred tax assets 
investment securities investment securities consist principally of debt securities issued by the us treasury and other us government agencies and corporations and investment in other securities  including mutual funds 
investment securities are classified into three categories and accounted for as follows held to maturity securities are debt securities that the company has the positive intent and ability to hold to maturity 
these securities are reported at amortized cost 
trading securities are securities which are bought and held principally for the purpose of selling them in the near term 
these securities are reported at fair value  with unrealized gains and losses included in current earnings 
available for sale securities are debt and equity securities not classified as either held to maturity or trading securities 
the company does not have available for sale securities 
gains and losses realized on the sales of investment securities are determined using the specific identification method 
the company s trading securities consist of mutual funds and relate to a company plan whereby certain individuals may forego immediate receipt of wages 
in connection therewith  the company establishes a liability for accrued wages and records the related compensation expense as services are performed 
further  the company segregates an amount of funds in investment accounts equal to the liability for accrued wages 
the investment accounts trading securities remain assets of the company  and are subject to the general creditors of the company 
upon transfer of the funds to the investment accounts  the employees direct the specific investment of the funds 
the changes in value in the investment accounts trading securities are recognized as unrealized gains and losses in the statements of operations  with a corresponding increase or decrease to research and development expense and the liability for employees wages and benefits 
unconditional supply commitment the company has the unconditional right to receive supplies originally aggregating million from aventis pasteur 
the company s policy is to review the current market prices of available supplies  if any  to assure that they remain above the stated aventis pasteur contract price of the materials and that the right to receive the supplies remains unimpaired 
aventis pasteur is one of the largest pharmaceutical vaccine manufacturers in the world 
the company monitors the financial performance of aventis pasteur to assure that they will continue to be able to perform under the contract  wherein the special order supplies are to be provided from supplies manufactured by aventis pasteur in large quantities and sold to many customers  including the us government  as part of aventis pasteur s basic franchise business 
the contract allows for inflation based increases in the per unit costs of the supplies which the company and aventis pasteur believe are sufficient to assure that there will be no future financial hardship incurred by aventis pasteur in the execution of the agreement 
item a 
quantitative and qualitative disclosures about market risk aphton s market risks are all immaterial 
investment securities consist principally of debt securities issued by the us treasury and other us government agencies and corporations and investment in other securities  including mutual funds 

